La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sumitomo Pharma Gestione

Gestione criteri di controllo 2/4

Sumitomo Pharma's Il CEO è Toru Kimura, nominato in Jan2016, ha un mandato di 8.58 anni. possiede direttamente 0.02% delle azioni della società, per un valore di ¥ 46.25M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 3.7 anni.

Informazioni chiave

Toru Kimura

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	8.7yrs
Proprietà del CEO	0.02%
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

Sep 12

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Aug 16

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Jun 26

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

AMMINISTRATORE DELEGATO

Toru Kimura (64 yo)

8.7yrs

Mandato

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Toru Kimura	Representative Director	8.7yrs	Nessun dato	0.020% ¥ 44.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Nessun dato	Nessun dato
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.4yrs	Nessun dato	0.0015% ¥ 3.4m
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.4yrs	Nessun dato	Nessun dato
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.3yrs	Nessun dato	0.0038% ¥ 8.5m
Koichi Kozuki	E.O. of R. Aff.	1.7yrs	Nessun dato	Nessun dato
Shigeyuki Nishinaka	Managing Executive Office	7.4yrs	Nessun dato	0.0020% ¥ 4.5m
Isao Shimizu	Executive Officer	1.7yrs	Nessun dato	Nessun dato
Kenji Ueno	Executive Officer	1.7yrs	Nessun dato	Nessun dato
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.4yrs	Nessun dato	Nessun dato
Adele M. Gulfo	Executive Officer & CEO of Biopharma Commercial Unit of Sumitomo Pharma America	1.7yrs	Nessun dato	Nessun dato
Tsutomu Nakagawa	Executive Officer	1.7yrs	Nessun dato	0.00076% ¥ 1.7m

2.0yrs

Durata media

63.5yo

Età media

Gestione esperta: Il team dirigenziale di 4506 è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Toru Kimura	Representative Director	8.3yrs	Nessun dato	0.020% ¥ 44.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Nessun dato	Nessun dato
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.3yrs	Nessun dato	0.0038% ¥ 8.5m
Tsutomu Nakagawa	Executive Officer	less than a year	Nessun dato	0.00076% ¥ 1.7m
Saeko Arai	Independent Outside Director	6.3yrs	Nessun dato	Nessun dato
Minoru Usui	Independent Outside Director	3.3yrs	Nessun dato	Nessun dato
Nobuhiro Endo	Independent Outside Director	5.3yrs	Nessun dato	Nessun dato
Hiroshi Niinuma	Director	less than a year	Nessun dato	Nessun dato
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.3yrs	Nessun dato	0.0065% ¥ 14.7m
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.3yrs	Nessun dato	Nessun dato
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.3yrs	Nessun dato	0.0035% ¥ 7.9m
Koji Fujimoto	Independent Outside Director	2.3yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4506 sono considerati esperti (durata media dell'incarico 3.7 anni).

Sumitomo Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to JP¥48.57 loss

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Consensus forecasts updated